Sentence examples for progression sensitivity from inspiring English sources

The presence of more than 3 metabolic complications discriminated between patients with and without renal progression (sensitivity, 81% and specificity, 67%) and death (sensitivity, 76% and specificity, 61%).

The preclinical sojourn time, transition rates between the stages of cancer progression, sensitivity of diagnostic tests, and the effect of different risk factors on cancer progression and sensitivity, all are important factors that should be taken into account in deciding about the best screening frequency and starting and ending ages of screening.

This study was designed to investigate the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) on tumour progression and sensitivity to 5′-deoxy-5-fluorouridine (5′-DFUR).

It requires multi-dimensional views and the integration of molecular interaction networks in the analysis of high-throughput data to define the variation of disease severity and progression, drug sensitivity and resistance, cell growth and differentiation, and pathogenesis elaboration.

It is important to think clinical lipidomics as the part of clinical trans-omics which was coined as a new emerging scientific discipline where clinical phenomes are integrated with molecular multiomics, in order to further understand molecular mechanisms of disease pathogenesis and progression, patient sensitivity to therapy and prognosis, and therapy design and development [3].

A better understanding of the mechanism by which Akt and FOXO3a are regulated, as well as their roles in cancer progression, drug sensitivity and resistance, may turn these proteins into crucial therapeutic targets and prognostic markers for breast cancer and other malignancies.

For predicting progression, a sensitivity of 66.7% was achieved at 100% specificity using cfDNA levels at 8 weeks.

Rgs16::GFP is a robust and faithful in vivo reporter of PDA progression and sensitivity to new chemotherapeutic drug regimens, including Axl-targeted agents.

Rgs16::GFP is therefore an in vivo reporter of PDA progression and sensitivity to new chemotherapeutic drug regimens such as Axl-targeted agents.

Tumour acidity is an inevitable consequence of the upregulated glycolytic flux induced by hypoxia, and dramatically affects cancer progression and sensitivity to therapy.

Changes in p53 status have been linked to disease progression, decreased sensitivity to chemotherapeutic agents and poor prognosis (Cabelguenne et al, 2000).